LGND Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ligand Pharmaceuticals Inc (LGND) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support, positive technical indicators, and significant catalysts such as FDA approvals for its partner's drugs. While recent financial performance shows a decline in net income and EPS, the revenue growth and gross margin improvement indicate potential for long-term value. The absence of significant insider or hedge fund activity, along with a neutral options sentiment, does not detract from the stock's positive outlook.
The technical indicators for LGND are positive. The MACD histogram is above 0 and positively contracting, suggesting bullish momentum. The RSI is in the neutral zone at 64.729, indicating no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading above key support levels with a pivot at 220.44 and resistance at 235.627. This indicates a strong upward trend.
FDA approval of Filspari for focal segmental glomerulosclerosis, benefiting Ligand through its partnership with Travere.
Analysts have consistently raised price targets, with the most recent targets ranging from $243 to $282, all with Buy ratings.
Strong revenue growth of 39.37% YoY and improved gross margin to 81.42%.
Significant drop in net income (-244.06% YoY) and EPS (-232.32% YoY) in the latest quarter.
No recent news or significant insider/hedge fund activity to further support bullish sentiment.
In Q4 2025, Ligand's revenue increased by 39.37% YoY to $59.67M, and gross margin improved to 81.42%. However, net income dropped by -244.06% YoY to $44.78M, and EPS fell by -232.32% YoY to 2.17. While profitability metrics declined, revenue growth and margin expansion indicate potential for long-term value.
Analysts have a strong Buy consensus on LGND, with recent price target increases from Citi ($282), H.C. Wainwright ($243), and BofA ($250). Analysts highlight the FDA approval of Filspari and the company's robust portfolio as key drivers for growth.
